Biodesix (BDSX) Set to Post Quarterly Earnings on Thursday

Key Points

• Biodesix is scheduled to report Q3 2026 results after market close on Thursday, November 5, with analysts expecting a loss of $0.75 per share and revenue of $27.49 million.
• The company exceeded expectations in its latest quarter, reporting a $0.71-per-share loss versus the $0.90 consensus estimate and revenue of $26.86 million versus $26.03 million expected. Analysts project full-year and next-year losses of $2.68 and $1.66 per share, respectively.
• Despite ongoing losses and high leverage, Biodesix holds a consensus “Moderate Buy” rating with a $36.25 price target; several analysts recently raised targets, while insiders have purchased 42,600 shares over the past 90 days.

Biodesix (NASDAQ:BDSX - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Biodesix to announce earnings of ($0.75) per share and revenue of $27.49 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Biodesix (NASDAQ:BDSX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The business had revenue of $26.86 million during the quarter, compared to analysts' expectations of $26.03 million. On average, analysts expect Biodesix to post ($2.68) EPS for the current fiscal year and ($1.66) EPS for the next fiscal year.

Biodesix Price Performance

BDSX stock opened at $22.86 on Thursday. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. Biodesix has a 12 month low of $5.26 and a 12 month high of $31.97. The firm has a market cap of $241.20 million, a P/E ratio of -7.21 and a beta of 0.56. The company's 50-day moving average price is $26.49 and its two-hundred day moving average price is $18.48.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of Biodesix from $27.00 to $35.00 and gave the stock a "buy" rating in a report on Monday, August 10th. HC Wainwright reissued a "buy" rating on shares of Biodesix in a research note on Thursday, October 22nd. Weiss Ratings upgraded shares of Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 8th. Finally, TD Cowen restated a "buy" rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $36.25.

Insider Transactions at Biodesix

In related news, Director Jack Schuler acquired 15,000 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $24.47 per share, for a total transaction of $367,050.00. Following the transaction, the director directly owned 555,810 shares in the company, valued at $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have purchased 42,600 shares of company stock worth $1,033,062. 23.20% of the stock is owned by corporate insiders.

About Biodesix

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.